title: Metabolically normal obese people are protected from adverse effects following weight gain.
abstract: BACKGROUND. Obesity is associated with insulin resistance and increased intrahepatic triglyceride (IHTG) content, both of which are key risk factors for diabetes and cardiovascular disease. However, a subset of obese people does not develop these metabolic complications. Here, we tested the hypothesis that people defined by IHTG content and insulin sensitivity as "metabolically normal obese" (MNO), but not those defined as "metabolically abnormal obese" (MAO), are protected from the adverse metabolic effects of weight gain. METHODS. Body composition, multiorgan insulin sensitivity, VLDL apolipoprotein B100 (apoB100) kinetics, and global transcriptional profile in adipose tissue were evaluated before and after moderate (~6%) weight gain in MNO (n = 12) and MAO (n = 8) subjects with a mean BMI of 36 ± 4 kg/m2 who were matched for BMI and fat mass. RESULTS. Although the increase in body weight and fat mass was the same in both groups, hepatic, skeletal muscle, and adipose tissue insulin sensitivity deteriorated, and VLDL apoB100 concentrations and secretion rates increased in MAO, but not MNO, subjects. Moreover, biological pathways and genes associated with adipose tissue lipogenesis increased in MNO, but not MAO, subjects. CONCLUSIONS. These data demonstrate that MNO people are resistant, whereas MAO people are predisposed, to the adverse metabolic effects of moderate weight gain and that increased adipose tissue capacity for lipogenesis might help protect MNO people from weight gain-induced metabolic dysfunction. TRIAL REGISTRATION. ClinicalTrials.gov NCT01184170. FUNDING. This work was supported by NIH grants UL1 RR024992 (Clinical Translational Science Award), DK 56341 (Nutrition and Obesity Research Center), DK 37948 and DK 20579 (Diabetes Center Grant), and UL1 TR000450 (KL2 Award); a Central Society for Clinical and Translational Research Early Career Development Award; and by grants from the Longer Life Foundation and the Kilo Foundation.
authors.forename: Elisa
authors.initials: E
authors.lastname: Fabbrini
authors.forename: Jun
authors.initials: J
authors.lastname: Yoshino
authors.forename: Mihoko
authors.initials: M
authors.lastname: Yoshino
authors.forename: Faidon
authors.initials: F
authors.lastname: Magkos
authors.forename: Courtney
authors.initials: C
authors.lastname: Tiemann Luecking
authors.forename: Dmitri
authors.initials: D
authors.lastname: Samovski
authors.forename: Gemma
authors.initials: G
authors.lastname: Fraterrigo
authors.forename: Adewole L
authors.initials: AL
authors.lastname: Okunade
authors.forename: Bruce W
authors.initials: BW
authors.lastname: Patterson
authors.forename: Samuel
authors.initials: S
authors.lastname: Klein
mesh_terms: D000273:Adipose Tissue / Q000378:metabolism / Q000503:physiopathology; D050154:Adiposity; D000328:Adult; D053299:Apolipoprotein B-100 / Q000097:blood; D015992:Body Mass Index; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D050155:Lipogenesis; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000378:metabolism / Q000503:physiopathology; D009765:Obesity / Q000097:blood / Q000503:physiopathology
chemical_list: D053299:Apolipoprotein B-100; D008079:Lipoproteins, VLDL